Oncology Intelligence Digest November 17, 2026 The FDA approved Roche’s oral SERD Wilserdly (giredestrant) with everolimus for ESR1-mutated…
Oncology Intelligence Digest November 17, 2026 The FDA approved Roche’s oral SERD Wilserdly (giredestrant) with everolimus for ESR1-mutated…